Entecavir versus lamivudine in the treatment of chronic hepatitis B patients with hepatic decompensation

Antiviral Therapy

Volumn 17, Issue 4, 2012, Pages 605-612

  Hsu, Yao Chun ^a   Mo, Lein Ray ^a   Chang, Chi Yang ^a   Perng, Daw Shyong ^a   Tseng, Cheng Hao ^a   Lo, Gin Ho ^a   Tai, Chih Min ^a   Lin, Chih Wen ^a   Hsu, Chia Chang ^a   Hsu, Chuan Yuan ^a   Huang, Shih Che ^a   Lin, Jaw Town ^a,b  

^a E DA HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ENTECAVIR; LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; BLOOD CLOTTING DISORDER; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG SAFETY; END STAGE LIVER DISEASE; FEMALE; HEPATITIS B; HUMAN; HYPERBILIRUBINEMIA; INTERNATIONAL NORMALIZED RATIO; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTHROMBIN TIME; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIVIRAL AGENTS; FEMALE; GUANINE; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER FAILURE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84861697827     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2027     Document Type: Article

References (35)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337:1733-1745. (Pubitemid 27527771)
2. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981; 318:1129-1133.
3. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988; 61:1942-1956.
4. Sheen IS, Liaw YF, Tai DI, Chu CM. Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis. Gastroenterology 1985; 89:732-735. (Pubitemid 15015286)
5. Liaw YF, Chen JJ, Chen TJ. Acute exacerbation in patients with liver cirrhosis: a clinicopathological study. Liver 1990; 10:177-184.
6. Weissberg JI, Andres LL, Smith CI, et al. Survival in chronic hepatitis B. An analysis of 379 patients. Ann Intern Med 1984; 101:613-616. (Pubitemid 15223297)
7. de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103:1630-1635.
8. Fontana RJ, Hann HW, Perrillo RP, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002; 123:719-727. (Pubitemid 34977078)
9. Chien RN, Lin CH, Liaw YF. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. J Hepatol 2003; 38:322-327. (Pubitemid 36286545)
10. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373:582-592.
11. Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acuteon-chronic liver failure. Hepatology 2011; 53:774-780.
12. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2:263-283.
13. EASL Clinical Practice Guidelines. Management of chronic hepatitis B. J Hepatol 2009; 50:227-242.
14. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50:661-662.
15. Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000; 33:301-307. (Pubitemid 30485234)
16. Perrillo RP, Wright T, Rakela J, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33:424-432. (Pubitemid 32119032)
17. Tsubota A, Arase Y, Suzuki Y, et al. Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B. J Gastroenterol Hepatol 2005; 20:426-432. (Pubitemid 40469345)
18. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125:1714-1722. (Pubitemid 37500436)
19. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354:1001-1010. (Pubitemid 43357804)
20. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354:1011-1020. (Pubitemid 43357805)
21. Woo G, Tomlinson G, Nishikawa Y, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010; 139:1218-1229.e5.
22. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009; 49:1503-1514.
23. Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009; 50:2001-2006.
24. Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010; 52:176-182.
25. Wong VW, Wong GL, Yiu KK, et al. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. J Hepatol 2011; 54:236-242.
26. Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011; 53:62-72.
27. Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, openlabel study. Hepatology 2011; 54:91-100.
28. Hung CH, Lu SN, Wang JH, et al. Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virus-related cirrhosis. J Gastroenterol 2003; 38:153-157. (Pubitemid 36372290)
29. Wong VW, Chan HL. Severe acute exacerbation of chronic hepatitis B: a unique presentation of a common disease. J Gastroenterol Hepatol 2009; 24:1179-1186.
30. Sarin SK, Kumar A, Almeida JA, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int 2009; 3:269-282.
31. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31:864-871. (Pubitemid 30169932)
32. Jeng WJ, Sheen IS, Liaw YF. Hepatitis B virus DNA level predicts hepatic decompensation in patients with acute exacerbation of chronic hepatitis B. Clin Gastroenterol Hepatol 2010; 8:541-545.
33. Gane EJ, Chan HL, Choudhuri G, et al. Treatment of decompensated HBV-cirrhosis: results from 2-years randomized trial with telbivudine or lamivudine. J Hepatol 2010; 52 Suppl 1:S4.
34. Chan HL, Wong VW, Hui AY, et al. Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B. Antivir Ther 2006; 11:465-471. (Pubitemid 44024854)
35. Wong VW, Wong GL, Tsang SW, et al. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. Antivir Ther 2008; 13:571-579. (Pubitemid 352016720)